These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24156018)

  • 41. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
    Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
    Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S; Hirose Y; Kawase T; Sano H
    J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
    Gilbert CA; Daou MC; Moser RP; Ross AH
    Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
    Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
    J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
    Yu G; Wu F; Wang E
    Cell Physiol Biochem; 2016; 38(4):1596-604. PubMed ID: 27081861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
    Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
    Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
    [No Abstract]   [Full Text] [Related]  

  • 53. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
    Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
    PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
    Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
    PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
    Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
    Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
    Trog D; Yeghiazaryan K; Fountoulakis M; Friedlein A; Moenkemann H; Haertel N; Schueller H; Breipohl W; Schild H; Leppert D; Golubnitschaja O
    Eur J Pharmacol; 2006 Aug; 542(1-3):8-15. PubMed ID: 16806166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.